NCT05797935

Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study aimed to assess changes in pancreatic fat content in people with diabetes on dapagliflozin (SGLT2 inhibitor) and beta cell function.

Detailed description

The study assessed and estimated the difference in pancreatic fat content in the patients of Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks. The investigators even estimated the correlation between two advanced MR techniques commonly used for quantification of pancreatic fat (PDFF and MR Spectroscopy)

Conditions

• Pancreatic Lipomatosis

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10mg Tab	Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content

Timeline

• Start date: 2021-08-01
• Primary completion: 2022-12-20
• Completion: 2022-12-31
• First posted: 2023-04-04
• Last updated: 2023-04-10

Locations

1 site across 1 country: India